Showing results (1001-1010 of 1,163) with videos related to

Sort By:
Pageof 117
Journal of the American Heart Association|June 11, 2025
Race and Ethnicity in Heart Failure Trials: Time to Update Recommended Categories for Global RelevanceMingming Yang, Toru Kondo, Pooja Dewan, et al.
ESC Heart Failure|April 1, 2018
Prevalence, clinical correlates, and outcomes of anaemia in multi-ethnic Asian patients with heart failure with reduced ejection fractionVera J Goh, Jasper Tromp, Tiew-Hwa K Teng, et al.
European Journal of Heart Failure|April 4, 2020
A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failureIziah E Sama, Rebecca J Woolley, Jan F Nauta, et al.
Global Heart|September 14, 2020
Management of Cardiovascular Disease Patients With Confirmed or Suspected COVID-19 in Limited Resource SettingsDorairaj Prabhakaran, Pablo Perel, Ambuj Roy, et al.
European Heart Journal|August 15, 2021
Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fractionAlice M Jackson, Pardeep S Jhund, Inder S Anand, et al.
JAMA Cardiology|March 5, 2025
Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HFKirsty McDowell, Kieran F Docherty, Ross T Campbell, et al.
European Journal of Heart Failure|May 15, 2024
Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trialMats Christian Højbjerg Lassen, John W Ostrominski, Silvio E Inzucchi, et al.
Circulation. Heart Failure|September 29, 2024
Finerenone Improves Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HFMisato Chimura, Mark C Petrie, Morten Schou, et al.
JACC. Heart Failure|June 9, 2023
Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy StatusAlexander Peikert, Parag Goyal, Muthiah Vaduganathan, et al.
European Journal of Heart Failure|April 11, 2026
Effects of Finerenone Across a Range of Heart Failure Duration: A Prespecified Analysis of the FINEARTS-HF TrialYasuhiro Hamatani, John W Ostrominski, Henri Lu, et al.
Pageof 117